Transformative Scientific Breakthrough Pioneered by Spencer Trask & Co. Venture Osiris Therapeutics NEW YORK, Jan. 16, 2025 ...
Hosted on MSN29d
FDA approves Mesoblast’s Ryoncil for SR-aGvHD treatmentMesoblast has gained US Food and Drug Administration (FDA) approval for its mesenchymal stromal cell (MSC) therapy, Ryoncil (remestemcel-L), to treat steroid-refractory acute graft versus host ...
RYONCIL is the only MSC therapy approved in the U.S. for any indication, and the only approved therapy for steroid-refractory acute graft versus host disease (SR-aGvHD) in children 2 months and ...
FDA approves Mesoblast's Ryoncil, the first U.S. MSC therapy, for children with steroid-refractory acute graft-versus-host disease. In a Phase 3 trial, 70% of SR-aGvHD patients responded to ...
中国首款干细胞疗法，它来了。近日，国家药品监督管理局（NMPA）官网显示，铂生卓越生物科技（北京）有限公司（下称铂生卓越）的艾米迈托赛注射液（商品名：睿铂生）上市，适应症为用于治疗14岁以上消化道受累为主的激素治疗失败的急性移植物抗宿主病（acute ...
SR-aGVHD is not just another medical term—it ... By greenlighting the first MSC-based treatment, the FDA is planting a flag on the frontier of regenerative medicine. The ability to reprogram ...
FDA新闻稿指出，Ryoncil是首款获得FDA批准上市的MSC疗法。 SR-aGVHD是一种严重且危及生命的疾病，通常发生于同种异体造血干细胞移植（allo-HSCT ...
这款名为“艾米迈托赛注射液”（人脐带间充质干细胞）产品的适应症同样为激素失败的急性移植物抗宿主病（aGVHD），对标刚刚获FDA批准的MSC细胞 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback